Recent progress in the treatment of sickle cell disease: an up-to-date review
Abstract Background Sickle cell disease is a fatal systemic condition characterized by acute painful episodes, persistent anemia, ongoing organ damage, organ infarction, and a markedly shorter average lifetime. It first appeared in the tropics' malarial zones, where carriers benefit from an evo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-04-01
|
| Series: | Beni-Suef University Journal of Basic and Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43088-023-00373-w |
| _version_ | 1797845809966874624 |
|---|---|
| author | Biswajeet Acharya Durga Prasad Mishra Binapani Barik Ranjan K. Mohapatra Ashish K. Sarangi |
| author_facet | Biswajeet Acharya Durga Prasad Mishra Binapani Barik Ranjan K. Mohapatra Ashish K. Sarangi |
| author_sort | Biswajeet Acharya |
| collection | DOAJ |
| description | Abstract Background Sickle cell disease is a fatal systemic condition characterized by acute painful episodes, persistent anemia, ongoing organ damage, organ infarction, and a markedly shorter average lifetime. It first appeared in the tropics' malarial zones, where carriers benefit from an evolutionary advantage by being shielded from malaria death. Due to demographic shifts, this crisis now affects people all over the world. In higher-income areas, such as vast swaths of Europe and North and South America, more children are born with the syndrome. Main body Over the last 10 years, a clearer knowledge of the change from fetal to adult hemoglobin has evolved. Further investigation into chimerism, genomics, mixed gene editing, and therapeutic reactivation of fetal hemoglobin has produced very promising findings. Between 2017 and 2019, three innovative medications for sickle cell disease were approved by the FDA thanks to previous advances, while many more treatments are now under development. Short conclusion To improve patient outcomes, various innovative medications that were created in the late 1990s and utilized to treat sickle cell disease are examined in this study. In our appraisal, we'll also focus on the most important developments of the decade. |
| first_indexed | 2024-04-09T17:44:57Z |
| format | Article |
| id | doaj.art-596b43c0f5a34a4ca54c9830aed8293a |
| institution | Directory Open Access Journal |
| issn | 2314-8543 |
| language | English |
| last_indexed | 2024-04-09T17:44:57Z |
| publishDate | 2023-04-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Beni-Suef University Journal of Basic and Applied Sciences |
| spelling | doaj.art-596b43c0f5a34a4ca54c9830aed8293a2023-04-16T11:22:11ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432023-04-0112111810.1186/s43088-023-00373-wRecent progress in the treatment of sickle cell disease: an up-to-date reviewBiswajeet Acharya0Durga Prasad Mishra1Binapani Barik2Ranjan K. Mohapatra3Ashish K. Sarangi4School of Pharmacy, Centurion University of Technology and ManagementSchool of Pharmacy, Centurion University of Technology and ManagementSchool of Pharmacy, Centurion University of Technology and ManagementDepartment of Chemistry, Government College of EngineeringDepartment of Chemistry, School of Applied Sciences, Centurion University of Technology and ManagementAbstract Background Sickle cell disease is a fatal systemic condition characterized by acute painful episodes, persistent anemia, ongoing organ damage, organ infarction, and a markedly shorter average lifetime. It first appeared in the tropics' malarial zones, where carriers benefit from an evolutionary advantage by being shielded from malaria death. Due to demographic shifts, this crisis now affects people all over the world. In higher-income areas, such as vast swaths of Europe and North and South America, more children are born with the syndrome. Main body Over the last 10 years, a clearer knowledge of the change from fetal to adult hemoglobin has evolved. Further investigation into chimerism, genomics, mixed gene editing, and therapeutic reactivation of fetal hemoglobin has produced very promising findings. Between 2017 and 2019, three innovative medications for sickle cell disease were approved by the FDA thanks to previous advances, while many more treatments are now under development. Short conclusion To improve patient outcomes, various innovative medications that were created in the late 1990s and utilized to treat sickle cell disease are examined in this study. In our appraisal, we'll also focus on the most important developments of the decade.https://doi.org/10.1186/s43088-023-00373-wAnemiaHemoglobinHematological disorderSickle cell disease |
| spellingShingle | Biswajeet Acharya Durga Prasad Mishra Binapani Barik Ranjan K. Mohapatra Ashish K. Sarangi Recent progress in the treatment of sickle cell disease: an up-to-date review Beni-Suef University Journal of Basic and Applied Sciences Anemia Hemoglobin Hematological disorder Sickle cell disease |
| title | Recent progress in the treatment of sickle cell disease: an up-to-date review |
| title_full | Recent progress in the treatment of sickle cell disease: an up-to-date review |
| title_fullStr | Recent progress in the treatment of sickle cell disease: an up-to-date review |
| title_full_unstemmed | Recent progress in the treatment of sickle cell disease: an up-to-date review |
| title_short | Recent progress in the treatment of sickle cell disease: an up-to-date review |
| title_sort | recent progress in the treatment of sickle cell disease an up to date review |
| topic | Anemia Hemoglobin Hematological disorder Sickle cell disease |
| url | https://doi.org/10.1186/s43088-023-00373-w |
| work_keys_str_mv | AT biswajeetacharya recentprogressinthetreatmentofsicklecelldiseaseanuptodatereview AT durgaprasadmishra recentprogressinthetreatmentofsicklecelldiseaseanuptodatereview AT binapanibarik recentprogressinthetreatmentofsicklecelldiseaseanuptodatereview AT ranjankmohapatra recentprogressinthetreatmentofsicklecelldiseaseanuptodatereview AT ashishksarangi recentprogressinthetreatmentofsicklecelldiseaseanuptodatereview |